111 patents
Page 4 of 6
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) In Pediatric Patients
15 Jul 21
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients using an anti-C5 antibody, or antigen binding fragment thereof.
Lori PAYTON, Scott T. ROTTINGHAUS, Rajendra PRADHAN, Stephan ORTIZ, Masayo OGAWA, Xiang GAO
Filed: 29 May 19
Utility
Compositions Comprising an ANTI-C5 Antibody
15 Jul 21
The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.
Yi WANG
Filed: 19 Jan 21
Utility
Biodegradable Activated Polymers for Therapeutic Delivery
24 Jun 21
Activated polymers comprising one or more backbone ester(s) are disclosed.
Christopher J. CHENG, W. Mark SALTZMAN, Junwei ZHANG
Filed: 28 Feb 17
Utility
Methods for Treating Diseases Associated with Ciliopathies
24 Jun 21
Methods of treating a ciliopathy-associated disease are disclosed, including administering to a subject in need thereof an effective amount of a compound that targets at least one G-protein coupled receptor.
Sophie SAUNIER, Luis BRISENO-ROA, Soraya SIN-MONNOT, Jean-philippe ANNEREAU, Marion DELOUS, Hugo GARCIA, Guillermo DEL ANGEL, Flora LEGENDRE
Filed: 12 Oct 18
Utility
Efficacy of an ANTI-C5 Antibody In the Prevention of Antibody Mediated Rejection In Sensitized Recipients of Kidney Transplant
24 Jun 21
A method for preventing AMR in a human kidney transplant recipient is provided.
Herman GRIFFIN, Xiang GAO, Rebecca VELEZ, Wei-Jian PAN
Filed: 27 Oct 20
Utility
Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
17 Jun 21
Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided.
Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA
Filed: 22 Feb 21
Utility
Alkaline Phosphatase Polypeptides and Methods of Use Thereof
10 Jun 21
Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof.
Walter C. VOEGTLI, Michael BARANELLO, Keith BOUCHARD
Filed: 9 Dec 20
Utility
Lysosomal Storage Disease Enzymes
10 Jun 21
The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
Anthony QUINN, Alex J. HARVEY
Filed: 9 Nov 20
Utility
Methods of Treating Neurofibromatosis Type 1 and Related Conditions with Alkaline Phosphatase
3 Jun 21
The disclosure features methods for treating at least one symptom of neurofibromatosis type 1, treating at least one symptom of dystrophic scoliosis, or inducing bone healing by administering a soluble alkaline phosphatase (sALP) to the patient.
Anna PETRYK
Filed: 9 Aug 19
Utility
Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
13 May 21
Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided.
Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA
Filed: 4 Dec 18
Utility
Solid Forms of Cerdulatinib
6 May 21
Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state.
Anjali Pandey, Julian Scott Northen, Philippe Fernandes, Ying Chen, Yuelie Lu, Sami Karaborni, Gus Kodersha
Filed: 16 Nov 20
Utility
Methods of Producing ANTI-C5 Antibodies
29 Apr 21
The present application relates to a method of producing an anti-C5 antibody (ravulizumab). wherein the method comprises: —culturing mammalian cells comprising a nucleic acid encoding the anti-C5 antibody in a cell culture production medium—Performing two or more steps selected from the group consisting of: a recovery step; purification by Protein A affinity chromatography, a low pH viral inactivation step; Purification by cation exchange chromatography; Purification by anion exchange chromatography; a virus reduction filtration step; and a concentration and diafiltration step
Hunter F. MALANSON, Kyle A. ZINGARO, Anjil GIRI, Justin WEAVER, Abraham FRIEDMAN, Jeffrey William HUNTER, Saranya SIVANANDAM, Jeffrey ZUGATES, Rahul GODAWAT
Filed: 27 Jun 19
Utility
Crystalline Particles of Bis-Choline Tetrathiomolybdate
1 Apr 21
Novel crystalline particles, methods for manufacture of crystalline particles, and solid unit dosage forms, particularly tablets or capsules, of bis-choline tetrathiomolybdate are provided.
Lars OLSSON, Viveca T. OLTNER
Filed: 6 Feb 19
Utility
Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
1 Apr 21
Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided.
Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA
Filed: 19 Aug 20
Utility
Liquid Formulations of ANTI-CD200 Antibodies
25 Mar 21
The present disclosure provides stable liquid pharmaceutical formulations comprising anti-CD200 antibodies or antigen-binding fragments thereof, and articles of manufacture and kits containing the formulations.
Dino MIANO, Bruce MASON
Filed: 18 Dec 18
Utility
Methods of Shifting an Isoelectric Profile of a Protein Product and Uses Thereof
4 Mar 21
Provided herein are methods shifting the isoelectric profile of a recombinant protein product and the use of such methods in the manufacture of recombinant protein products.
Hunter F. MALANSON, Pratik JALURIA, Rachael ALFORD
Filed: 11 Jun 20
Utility
High Throughput Method for Measuring the Protease Activity of Complement C3 Convertase
28 Jan 21
Provided herein are high throughput methods for measuring the protease activity of the complement C3 convertase by detecting the consumption of C3 or the production of C3a in vivo and in vitro.
Christen D. FORBES
Filed: 21 Mar 19
Utility
Process for Preparation of Bis-Choline Tetrathiomolybdate
30 Dec 20
A process is provided for the production of bis-choline tetrathiomolybdate, the process comprising reacting a choline salt with ammonium tetrathiomolybdate, wherein the choline salt is a hydroxide, acetate, or halide choline salt, wherein the process comprises: combining the choline salt with a first mixture of ammonium tetrathiomolybdate in water, wherein a molar excess of choline salt to ammonium tetrathiomolybdate is used, for a first reaction period to provide a first reaction mixture; subjecting the first reaction mixture to a reduced pressure for a second reaction period to provide a second reaction mixture; and, isolating bis-choline tetrathiomolybdate from the second reaction mixture, wherein isolating bis-choline tetrathiomolybdate comprises adding ethanol to the second reaction mixture.
Johan Anders WENNERBERG, Hans Roger Marcus MÃ…RTENSSON
Filed: 14 Feb 19
Utility
Polypeptides That Bind Complement Component C5 or Serum Albumin and Fusion Proteins Thereof
23 Dec 20
The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin.
Bridget PUFFER, Julian CHANDLER, Nimish GERA, Douglas L. SHERIDAN, Siddharth JINDAL, Paul P. TAMBURINI
Filed: 10 Jul 18
Utility
Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients by an Inhibitor of Complement
16 Dec 20
Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglohinuria (PNH).
Leonard BELL, Russell P. ROTHER, Mark J. EVANS
Filed: 22 Jan 20